Advanced Therapies Week 2022 | Trends and innovations within the advanced therapy sector

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, gives an overview of the future of the cell and gene (CGT) industry, including advances in gene editing, enzymes, and the delivery of advanced therapies. Whilst cell therapies have been effective at targeting hematological malignancies, treating solid tumors remain a challenge due to the immunosuppressive microenvironment. Dr Levine describes the addition of novel modalities such as radiotherapy, vaccines, and oncolytic viruses to overcome this barrier. This interview took place at Advanced Therapies Week 2022.